TherapeuticsMD, Inc.
TXMD
$0.9962
-$0.0138-1.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 21.94% | 133.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.94% | 133.76% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 21.94% | 133.76% | |||
| SG&A Expenses | -32.90% | 6.24% | |||
| Depreciation & Amortization | 4.17% | -46.67% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.37% | -0.50% | |||
| Operating Income | 63.68% | 27.14% | |||
| Income Before Tax | 114.64% | 46.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 120.11% | 46.00% | |||
| Earnings from Discontinued Operations | 428.57% | -5.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 141.38% | 44.13% | |||
| EBIT | 63.68% | 27.14% | |||
| EBITDA | 72.21% | 23.62% | |||
| EPS Basic | 141.48% | 44.13% | |||
| Normalized Basic EPS | -104.89% | 45.47% | |||
| EPS Diluted | 140.86% | 43.28% | |||
| Normalized Diluted EPS | -104.89% | 45.47% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||